The aim of the ACTIVATE trial is to evaluate the impact of a supervised aerobic exercise intervention on chemotherapy-related cognitive changes (CRCC) in women diagnosed with early stage breast cancer. Chemotherapy-related cognitive changes (CRCC) are reported by up to 75% of breast cancer survivors during treatment and symptoms persist in 35% of survivors after treatment. Aerobic exercise is associated with improved quality of life in breast cancer survivors and holds promise as an intervention to prevent or mitigate CRCC.
British Columbia is in a unique position to be a leader in addressing the knowledge translation gap between exercise programming in cancer care and clinical practice. Currently, cancer care services are primarily delivered by the distributed sites of the BC Cancer Agency, which all reside in one health authority. This allows for a coordinated approach to knowledge translation that has provincial reach. Furthermore, BC is the only province to have a provincial tele-health system called HealthLink BC, which includes access to Qualified Exercise Professionals (QEP).
The SUCCESS BC project is partnering with the BC Cancer Agency to develop a model of service delivery that addresses key barriers to translation of a strong body of research into practice, by: 1) providing access to evidence-informed and vetted exercise information and guidance through QEP at HealthLink BC to extend the supportive care services available at BC Cancer Agency sites; and 2) a referral process for the healthcare professionals (HCP) of BC Cancer Agency to connect their patients to these services from a recognized, trusted source.
The True NTH lifestyle management initiative is a trial undertaken by Movember and Prostate Cancer Canada, designed as a community exercise feasibility study for prostate survivors. The 12-week program provides, twice weekly group supervised exercise sessions at community centers around Vancouver, and online access to educational materials for participants.
The program is run across Canada with Vancouver currently hosting 2 community centers at Creekside (Olympic Village) and Marpole (59th Ave) on either Monday/Wednesday's or Tuesday/Thursdays.
If you are a prostate cancer survivor and are interested in participating in a 12-week exercise program, please click here.
Understanding the unique challenges of being a young woman with breast cancer: a qualitative study for developing a lifestyle intervention program.
In Canada, the average age at diagnosis of early stage breast cancer is between 50-69 years. However, approximately 18% of breast cancer diagnoses are in women 45 years or younger. Breast cancer is the leading cause of cancer-related death and disability in Canadian women under 45 years of age.
Younger women with breast cancer face unique challenges in adoption of exercise and weight management practices when compared to those in older women, including financial concerns, competing daily demands (i.e., employment, relationships, young families), physical body changes, and social isolation.
Therefore, the development of interventions specifically tailored to younger women is warranted. The current study aims to form a focus group to gather more information about the challenges younger women with breast cancer face, and to gain a better understanding of what types of interventions are most effective in improving their quality of life through a lifestyle intervention.
This study is currently not recruiting participants.
The CO.21 Colon Health and Life-Long Exercise Change (CHALLENGE) trial undertaken by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) is designed to determine the effects of a structured physical activity intervention on outcomes for survivors of high-risk stage II or III colon cancer who have completed adjuvant therapy within the previous 2–6 months. The trial is a multi-site trial across Canada and Australia.
The Trial is running at the BCCA-Vancouver site. If you are being treated there for colon cancer and are interested in the trial, please talk to your oncologist.


text:
Steve Hackett announces the release of Genesis Revisited Live: Seconds Out & More on 2nd September (vinyl follows on 25th November)
by Unqualified-Kritic | Jul 5, 2022 | News
1st July 2022: Legendary guitarist Steve Hackett is pleased to announce, 'Genesis Revisited Live: Seconds Out & More', the visual document of his 2021 UK tour celebrating the classic Genesis live album. Set for release on the 2nd September 2022 (with vinyl following on the 25th November), it sees Steve and his band perform 'Seconds Out' in full & in sequence, as well as a selection of solo material including tracks from his most recent studio album 'Surrender of Silence'.
Watch the band perform the Genesis track 'Squonk' here:
Steve comments: "I'm so happy to release my Seconds Out & More show… A spectacular night with a band on fire tearing into that magic music combining the true spirit of Genesis with a fresh virtuosic approach and an extraordinary sound under amazing lights. This show is a feast for both ears and eyes. The best of so many worlds!"
'Genesis Revisited Live: Seconds Out & More' will be available as Limited 2CD + Blu-ray & Limited 2CD + DVD, both including 5.1 surround sound, behind the scenes documentary & promo videos. Steve Hackett and his band comprise Roger King, Rob Townsend, Jonas Reingold, Nad Sylvan & Craig Blundell, and they were joined by Amanda Lehmann as special guest on the night.
It will also be available as Ltd Gatefold 180g 4LP+2CD, and as Digital Audio Album (in 16 & 24bit). Pre-order now here: https://stevehackett.lnk.to/GenesisRevisitedLive-SecondsOutAndMore
The full track-listing is as follows:
1.Apollo Intro
2. Clocks – The Angel Of Mons
3. Held In The Shadows
4. Every Day
5. The Devil's Cathedral
6. Shadow Of The Hierophant
7. Squonk
8. The Carpet Crawlers
9. Robbery, Assault And Battery
11. Firth Of Fifth
12. I Know What I Like (In Your Wardrobe)
13. The Lamb Lies Down On Broadway
14. Musical Box (Closing Section)
15. Supper's Ready
16. The Cinema Show
17. Aisle Of Plenty
18. Dance On A Volcano
19. Los Endos
Steve Hackett & his band have just completed a run of shows in New Zealand and Australia, and will continue their 'Seconds Out & More' tour in Japan, Europe and North America throughout the rest of year. In September and October 2022, they will present their 'Foxtrot at Fifty' 25-date tour in the UK. For the full list of dates and to buy tickets go to HackettSongs.com.
About Steve Hackett
Steve Hackett joined Genesis at the beginning of 1971 and gained an international reputation as the guitarist in the band's classic line-up alongside Peter Gabriel, Tony Banks, Mike Rutherford and Phil Collins. Hackett's intricate guitar work was a key element of Genesis' albums from Nursery Cryme (1971) to Wind And Wuthering (1977) including the classic Selling England By The Pound.
After leaving Genesis at the end of 1977, Hackett's solo career, which now spans more than 30 albums, has demonstrated his extraordinary versatility with both electric and acoustic guitar. Hackett is renowned as both an immensely talented and innovative rock musician and a virtuoso classical guitarist and composer and this was recognised in 2010 when he was inducted into the Rock Hall Of Fame. He has also worked alongside Steve Howe of YES in the supergroup GTR.
Hackett's compositions take influences from many genres, including jazz, classical and blues. For his later studio works The Night Siren (2017) and At The Edge Of Light (2019) Hackett has explored the influences of world music. Recent tours have seen Hackett celebrate his time with Genesis including a spectacular 2018 tour in which he realised a long-held ambition to perform the works of Genesis live with his band and an orchestra.
The lockdown enforced by the 2020 global pandemic has proven to be a particularly creative period for Hackett. He began by releasing Selling England by the Pound & Spectral Mornings: Live at Hammersmith, a live recording of 2019's hugely successful tour celebrating that Genesis classic together with the 40th anniversary of one of his most-loved solo albums. Lockdown also gave Hackett the opportunity to write and record two new studio albums, the UK Classical Chart hit Under A Mediterranean Sky and the forthcoming Surrender of Silence.
STEVE HACKETT Online:
www.hackettsongs.com
www.facebook.com/pages/Steve-Hackett/123101228589
www.twitter.com/HackettOfficial
http://hackettsongs.com/tour.html
INSIDEOUTMUSIC Online:
www.twitter.com/insideouteu

redpajama_set_name: RedPajamaCommonCrawl


text:
The Northamptonshire Battlefields Society is hosting a full-day conference to commemorate the 550th anniversary of the battle of Edgcote.
The conference will take place at the Abington Park Museum, Park Avenue South, Northampton, NN1 5LW, from 10.00 a.m. to 4.15 p.m.
Speakers will include:
Mike Ingram: local historian and Chair of the Northamptonshire Battlefields Society
Phil Steele: Trustee of the Battlefields Trust
Harvey Watson: Wars of the Roses historian and editor of Battlefield magazine
Graham Evans: Secretary, Northamptonshire Battlefields Society
Professor Ann Parry Owen and Dr Jenny Day: from the University of Wales Centre for Advanced Welsh and celtic Studies, who will provide a unique insight into the battle using sources rarely consulted by writers in English
Tickets will be £35.00 (£30.00 to Battlefields Trust or Northamptonshire Battlefield Society members).
Tickets are available at https://www.eventbrite.co.uk/e/edgecote-1469-a-study-day-member-offer-tickets-58377428460
Ticket price includes refreshments, a buffet lunch and car parking.


text:
Home / Entertainment / Movies
'The Hater' Ending Explained: Tomasz gets vengeance with [spoiler's] death, will that end his menace?
Although 'The Hater' doesn't end with a cliffhanger, towards the end, it shows Tomasz blackmail Beata when she reveals to him that she's aware of his involvement in the mass shooting
By Chaitra Krishnamurthy
Updated On : 00:11 PST, Jul 29, 2020
With the story of a dishonest law student turned devious PR agent, Netflix's latest Polish thriller drama 'The Hater' makes for a compelling watch. Besides the anti-hero's dark characteristics, it is his intentions with fellow humans and society that aces at boggling your mind. Perhaps, this could also be the reason why we can't stop wondering what direction would Tomasz Giemza (Maciej Musialowski) head towards despite achieving his ultimate goal.
When Tomasz realizes that his only chance at being with Gabi Krasucka (Vanessa Aleksander) was snatched away by her parents Mr and Mrs Krasucka, who have also started to despise him, the young man decides to use his professional skills to wreak vengeance on the family that disowned him.
After impressing his boss Beata (Agata Kulesza) with his "yellow hands" social media trend that causes the fall of a fitness instructor as demanded by their client, Tomasz is asked to take up the case of politician Pawel Rudnicki (Maciej Stuhr). While his job requires him to jeopardize Rudnicki's position to serve the interest of his opposition, Tomasz approaches the situation quite differently, mainly to cater to his desperation to get back at Krasuckas.
In the chase to prove his abilities to the parents of the love of his life and win the praise of his boss Beata, Tomasz enters the realm of the dark web to enlist the help of a gamer known by the handle Guzek, also a far-right activist. Guzek's blog is filled with hate messages for non-Christians and Rudnicki for supporting refugees and this serves as the perfect opportunity for Tomasz to execute his highly dangerous plan, keeping his identity hidden.
As days pass, Tomasz's plan starts to play out perfectly as he finds a place for himself in Rudnicki's party as a volunteer, thus getting access to the most confidential information regarding the campaign and using the same to propel Guzek. However, Tomasz, who is driven more by his wrath for the Krasuckas, chooses to not tell Beata about his inner workings with Guzek.
Tomasz works yet another plan to convince Rudnicki to organize a meeting of his support committee only days before the elections to materialize his evil plan. When everybody gathers at the event, including Gabi's entire family, Guzek breaks in and starts to open fire, killing Gabi's sister Natalie and Rudnicki. However, instead of helping Guzek escape before the cops intervene as per the original plan, Tomasz himself takes him down and then surrenders him to the police. Being the cunning human that he is, Tomasz uses this opportunity to come across as a hero who saved many by a mass murderer along with winning Gabi's family's trust back.
Although 'The Hater' doesn't end with a cliffhanger, towards the end, it shows Tomasz blackmail Beata when she reveals to him that she's aware of his involvement in the mass shooting. This is when you start to wonder if there's anything that could ever stop Tomasz's villainous streak despite him getting everything he once yearned for. It further makes you think about the influence the dark web and social media have had on Tomasz, providing him with the power to cause more destruction.
It seems like Gabi's return alone wasn't enough to put an end to his menace, as he has grown into a full-grown criminal, who feels no remorse and seeks sadistic pleasure from else's loss. 'The Hater' will be available to stream on Netflix from July 29.
If you have an entertainment scoop or a story for us, please reach out to us on (323) 421-7515


This weeks theme is small scale, the smallest thing I've ever photographed is a hairy shrimp. It basically looks like a speck in real life. I'm not sure if I like photographing things this small, I haven't made up my mind. Theres an element of accomplishment when its in focus (they flimflam about a lot) but when you genuinely cannot see the thing in anything other than the screen on the camera it detracts from observing the wildlife. However, the other part of my mind thinks its amazing I can appreciate such smallness whereas other divers (without cameras) would not be able to.
See all the other photo Friday entries (and submit your own) for 'Small Scale' here.
We all live in a yellow submarine, a yellow submarine, a yellow submarine.
If only, that'd be very cool (as long as it had big viewing windows).
See all the other photo Friday entries (and submit your own) for 'Yellow' here.
Apologies for the lack of posts recently, my new little baby has been keeping me plenty busy.
This week's theme is Creature so heres some wee frog fish from Raja Ampat to brighten you Friday morning.
To see all the other photo Friday entries (and submit your own) for 'Creature' here.
This weeks theme is Still Life, so here is wishing everyone a very belated Happy Easter with my entry this week (I'm sure some of you are still finishing off the chocolate eggs so it still counts).
To see all the other photo Friday entries (and submit your own) for 'Still Life' here.


It is very rare in project management field when you met such all-rounders who have expertise in many subjects. Johanna Rothman, commonly known as "Pragmatic Manager" is one of them. She is the owner of Rothman consulting group, Inc.
Johanna Rothman is a very popular and experienced consultant, author, speaker and product development manager. She helps and counsels people seeking services of product development.
She helps in product launch by making clients realize the options for product management. Her services also include agile transformation.
Her organization helps in managing risks. Moreover, she write blogs for professionals about hiring people and project management. She loves to write about change management both on personal and professional scale.
She has been a technical editor of Techwell. She has worked program and project management as well. She is also the author of books namely "Manage It", "Hiring Geeks That Fit" and "Manage Your Project Portfolio". In addition, she wrote "Hiring Geeks That Fit" and several others.
Johanna helps professionals in working with managers and leaders for seizing opportunities. Johanna is the author Award winning books including Manage it! Your Guide to Modern Pragmatic Project Management.
Common Problems Encountered in Product development.
Mistakes of Project Managers and their Remedies.
New Trends of Agile Software development in 2018.
Best Practices to Implement Change.
Biggest Mistakes Committed by Interviewers.
Useful Practices for Risk Management.
Problems Encountered in working with remote teams.
Exact Role of Scrum Master.
Advice for New Project Managers.
TaskQue: First of all, we would like to know what really inspired you, in choosing product development management as career.
Johanna Rothman: I started my professional career as a software developer. I loved solving problems and had such fun programming. I didn't realize I was "developing products" until my second job.
In that job, I had responsibility for a product that the previous developer hadn't quite finished. Yet, the customers were using it and loved it–as far as it went. The customers wanted more.
I had to release small changes fairly often and they loved the way the "product evolved." (A customer's words.) That's when I realized I wasn't just a programmer; I was a product developer. That started to change how I thought about my role.
When I started as a consultant, I realized many of my previous employers–and I suspected new clients–had the same problem. They thought they created systems, not products. If I could help them change how they thought, they might be able to do a better job.
TaskQue: You train people about product development, what are the common issues you have witnessed in various products development.
The managers spend too much time thinking about which products to start and finish. That means the teams are under schedule pressure before they even start.
Someone (a manager/customer/some stakeholder) wants an accurate estimate at the start of a project. That's the time we know the least about the requirements, never mind the code base.
People believe that multitasking works.
The too-much-time thinking (and not deciding) is a project portfolio problem. Once organizations start to manage their project portfolios, they make decisions faster and stop the multitasking.
The estimation problem is often because the people outside the team think they have articulated the requirements and people "should" be able to estimate.
I've seen multitasking issues at every level of the organization. We don't multitask well at all. We can fast switch if we get to a stopping point.
TaskQue: Being an experienced product development manager, what mistakes do you find common among project managers, and what remedies do you suggest?
Thinking they won't need to re-plan the project.
Trying to optimize for each person, instead of the project.
Committing on behalf of the team, instead of asking the team.
I have yet to see a project I didn't need to re plan. Instead, I like to use deliverable-based rolling wave planning to plan the major milestones (or deliverables) and re plan at least as often as once a month.
We have data that says that flow efficiency (where we optimize for a team's output) is more productive and more effective than resource efficiency (where we optimize for a person). If project managers ask a team to finish work, they will see more throughput.
And, when project managers commit on behalf of a team, they don't know what they're committing to. It doesn't make sense to commit a team to a date or a deliverable without asking the team their opinion.
TaskQue: What's your point of view on agile software development? What trends do you see in upcoming years?
Johanna Rothman: As far as I can see, agile has jumped the shark. The problem is that people have co-opted the agile words without adopting the agile mindset and practices. That's why I wrote Create Your Successful Agile Project.
TaskQue: What do you think about change management? What are the key factors to manage change in a project successfully?
Johanna Rothman: Projects are full of change! I like to assume that change will occur and we need to expect and manage for change.
As to change in the organization? I like top-down, bottom-up, and sideways approaches to change. The first thing I like to consider is this: What is the smallest change we can make to become successful?
In projects and programs, I plan to iterate on the planning and delivery once we deliver something. It's the same idea for transformation work.
TaskQue: At your blog. We found a lot of posts related to tips related to recruitment interviews, What are the biggest mistakes interviewees commit during interviews?
Johanna Rothman: I find lack of preparation on the part of the interviewers and the candidates to be the biggest problem.
Interviewers need to prepare their behavior-description questions. Candidates need to prepare the stories of their careers, to answer those questions. In addition, candidates need to prepare questions to ask of the interviewers.
TaskQue: What do you recommend for risk management? What are the best practices regarding risk management.
Johanna Rothman: In my experience, you can manage risks when you have small deliverables and show progress every day or so. Risks become quite large and come true when the project team delays their integration or works on large requirements without feedback.
Plan and deliver in small chunks, such as one or two days. Now you can see if the deliverables are in trouble quite early.
Ask about risks that surprised us in a previous project. What is the likelihood of that happening again?
What can we deliver and get feedback about early in the project to reduce the unknowns and risks later?
What kinds of experiments can we try to see how to work better?
TaskQue: Remote working trend has been very common these days. What challenges usually project managers face to manage remote teams and what remedies do you suggest?
The people don't have the skills and capabilities they need to do their job as a team.
They are separated by so many time zones that meetings are painful.
They don't ever meet in person so they have a difficult time building trust with each other.
Too many managers don't know what skills and capabilities the team needs. If the project manager can listen to the team, the project manager will see what the team sees.
As for the too many time zone problem, I recommend a project manager explain that problem to the managers who created this team. The PM can explain the Cost of Delay and the costs of asking a question with this team. It's crazy for teams that can't easily meet to try to work together.
The first thing a distributed team needs is to build respect and trust between the team members. Having everyone work together for one or two weeks is inexpensive compared to the costs of delay when people don't believe the best of each other.
TaskQue: In an interview, you stated that scrum master should not be involved in coding level. What do you think is exactly the role of scrum master? To what extent, he should be involved in the organization?
Johanna Rothman: A Scrum Master facilitates the team's process. If a Scrum Master is coding or testing, the SM is not facilitating the team's process. (Take a look at the Scrum Guide for more specifics.) The SM cannot be a part-time SM if the team is new to Scrum. That doesn't work. It's possible a team accustomed to Scrum doesn't need a SM, but that takes a lot of work.
TaskQue: You have been working in the field for a long time. Which personalities have inspired you? Who do you think are the shining stars in the community?
Johanna Rothman: Gerald M. Weinberg. I have also learned a ton from Tom DeMarco, Tim Lister, Esther Derby, and Don Gray. I don't know how to discuss "shining stars" so I'll leave that alone.
TaskQue: Being a women in project management field, you are inspiration for thousands of women working in this field. What would you like to recommend to those ladies who wish to enter this field.
Johanna Rothman: Thank you! I don't think of myself as inspiration for anyone, so it's nice of you to say that. As for people who want to enter the project management field, here's my advice: learn the dynamics of your projects, so you can think clearly about the risks and this project's uniqueness. If I can add one more thing, it's this: work with other people as much as possible in the project. Command-and-control project management doesn't work (and never did), so understand how you can work with your team.
TaskQue: Apart from your professional life, what are your hobbies and interests? How much do you believe in work-life balance?
Johanna Rothman: I said this in Manage Your Job Search: There is no such thing as work life balance. There is only life. Live it.
I like to read, cook, and I walk a lot so I can stay in shape. I also love to travel and meet new people.
TaskQue: Technological advancements are reshaping project management. businesses are implementing various tools for increasing efficiency. TaskQue is one of the emerging task management software. What are your thoughts on the user experience of TaskQue?
Johanna Rothman: You probably won't like this answer.
I worry that you talk about people as resources. People are resourceful. However, they are not resources. I wrote about this in People Are Not Resources. You might also want to see what I say about flow efficiency and resource efficiency.
Think about how to move projects to done, not what people do and you'll be on a better track.


High Solids Equal A Higher Degree of Front End Forgiveness.
The ALUMABOND HS premium spray applied paint system manufactured by Titan Coatings, Inc. is an industrial polyester baking enamel designed for aluminum extrusion applications. ALUMABOND HS delivers AAMA 2603 compliance, and because it is engineered with high solids, offers the greatest degree of front-end forgiveness. It is tough – premium exterior grade U.V. to maintain color, and scratch resistant proprietary resins to deliver exterior durability and cleanability. But it is also friendlier to the environment with industry leading VOC of <2.6 lbs/gal and easier going on, with higher blister resistance resulting in much less wasted metal.
ALUMABOND HS coatings can be formulated in a wide range of glosses and colors, and are specially formulated for difficult profile penetration and coverage, wide DFT applications, and overall superior electrostatic coating line applications. Coating can be applied single coat or over primer and formulated to meet demanding VOC regulations (< 2.6 lbs/gal). ALUMABOND HS is an excellent choice for interior and exterior construction products.
Upgrade your coated aluminum product today with Titan ALUMABOND HS.


Medicare plans rely on Insight into at-risk populations and operational efficiency to maximize Star bonuses and minimize expenses. CSS Health's broad range of integrated medication management solutions helps Medicare plans like yours meet or exceed Star targets, with rapid returns on investment as high as 400%.
CSS Health's population data segmentation technology includes pharmacy, medical, and lab claims to identify members who might be likely to incur unusual expenses due to complex medication regimens, poor adherence, or chronic disease. By simplifying formulary management and identifying at-risk populations sooner, plans also reduce costs by eliminating redundant or inappropriate therapies.
Adherence is essential for maintaining or improving Star ratings, as well as other quality and wellness programs. Our configurable packaging systems use color-coded, individualized, by-day blister-packs to make it easier to follow complicated regimens.
Telehealth outreach services supplement these offerings by coaching members on how to follow their medication regimens and monitoring their progress. This integrated process connects members to providers, pharmacies, and support resources to create a unified member experience, which in turn drives improved Part C & D Star ratings.
CSS Health's proactive outreach programs help people feel valued as individuals. Access to lower-cost generic drugs and wellness services defray often frightening medication expenses. Person-to-person contact reassures members that someone cares, especially among the newly ill and populations with complicated conditions. The result is happier, healthier members, and greater satisfaction with their Medicare plan.
Whether turnkey outsourced offerings or supplemental programs for targeted operational needs, CSS Health tailors its solutions for each Medicare plan customer. For more information on our Medicare-specific products and services, click on the links below.


By no means was Tuesday's marquee matchup against Syndergaard one of Fernandez's finest performances. Somehow, though, he managed to hold his own even when he wasn't at his best and Syndergaard was sensational.
In the microcosm of the first two innings, Syndergaard retired all six batters he faced, whiffing five of them. Fernandez, meanwhile, gave up a run on three hits and the same number of walks.
Syndergaard struck out 12 in seven innings.
After those first two taxing innings, though, Fernandez found his rhythm and finished by retiring the final 10 Mets batters he faced, including the last four on whiffs. And as he was putting the Mets on lockdown, the Marlins found a way to put a run on the board off Syndergaard.
Derek Dietrich's two -out single in the fourth made it a 1 -1 game.
is Frank Robinson, who is seven hits in front of him at No. 33.
But it was the eighth, after Syndergaard was gone, that the Marlins broke through. Dee Gordon culminated his Marlins record 16 pitch at bat against Jim Henderson with a leadoff single, then stole second.
The previous Marlins record was shared by Gregg Zaun and Mike Lowell, who had 15 pitch at bats, Zaun in 1998 and Lowell in 2001. Gordon fouled off 11 straight pitches during his at bat before blooping a single to left.
Ricky Gutierrez holds the modern day record with a 20- pitch at-bat.
run with a sacrifice fly.
That gave the Marlins a 2 -1 lead.
In his new late- inning role, David Phelps came on and delivered two scoreless innings, and A.J. Ramos closed out the win in the ninth to bring the Marlins back up .500 with a 3- 3 record.
The Marlins are in position to sweep the defending National League champs, who have now lost four straight, with a win on Wednesday.


text:
thewritelife61
How pop culture influences us
The White Stuff
March 27, 2017 March 27, 2017 / thewritelife61
It's hard to imagine anyone with a more versatile or longer-lasting occupation than Betty White. During her career, she's starred in 12 sitcoms, had recurring roles on 17 shows, and appeared in another 45 series. In addition, she was in 14 movies; 18 movies made for television; and 305 different shows as herself, including 326 episodes of Match Game, 85 guest spots on the $10,000 Pyramid, 52 appearances on Entertainment Tonight, and 40 times on To Tell the Truth.
Born January 17, 1922 in Oak Park, Illinois, Betty was an only child. Her family moved to California when she was quite young. Her original goal was to become a Park Ranger, but that career was closed to women at that time. She started her entertainment career in radio, because she was told she was not photogenic. When World War II broke out, she joined the American Women's Voluntary Services. She was briefly married to Dick Barker, a pilot; they married and divorced in 1945. In 1947 she married Lane Allan, an agent, but they divorced in 1949.
Her career took a major leap in 1952 when Life with Elizabeth was picked up by the network. Betty was the star and producer of the show from 1952-1955. Her show gave her total control both behind and in front of the camera. She was the first woman to produce a sitcom. She was only 28 years old and living with her parents when this opportunity presented itself.
During the 1950s Betty would also star in the sitcom Date with the Angels, as Vickie Angel. Vickie and her husband, an insurance salesmen, involved their friends and neighbors in a variety of comic situations. She also appeared on variety shows such as Jack Paar Tonight, as well as The Betty White Show, a talk show. In 1956, she began an alliance with the Tournament of Roses parade which she co-hosted for 19 years.
The 1960s found her starring in her first movie, Advise and Consent in 1962, portraying Kansas senator Elizabeth Ames Adams. She also began her long partnership with game shows, earning the title, "First Lady of Game Shows." It was when she appeared on Password that she met her third husband, Allen Ludden, who was the host. They married in 1963 and were happily living life until his death in 1981. (Note: Wisconsin claims Allen Ludden because he was born in Mineral Point in 1917.)
LOS ANGELES, CA – MAY 17, 1976: (L-R) "The Mary Tyler Moore Show" co-stars – Ed Asner, Betty White, Mary Tyler Moore and Ted Knight – all won awards at the Academy of Television Arts & Sciences 28th Annual Primetime Emmy Awards held at the Shubert Theatre on May 17, 1976 in Los Angeles, California. (Photo by TVA/PictureGroup/Invision for the Academy of Television Arts & Sciences/AP Images)
In the 1970s, Betty re-entered the television series realm. She guest-starred on the Mary Tyler Moore Show during its fourth season as television host Sue Ann Nivens, the Happy Homemaker. She was such a hit that she became a regular for the rest of the series' run. In 1977, she and Georgia Engel starred in The Betty White Show (not to be confused with the talk show in the 1950s) which only lasted one season. Because of her affiliation with the Mary Tyler Moore Show, the Tournament of Roses replaced her as host, and she then took on the task of co-hosting the Macy's Thanksgiving Parade for ten years.
In the 1980s, at age 60, Betty's career continued to steamroll. She became a regular on Mama's Family, which aired from 1983-86. In 1985, she accepted the role of Rose Nyland on The Golden Girls. Originally slated for the part of Blanche, it was suggested that Rue McClanahan and Betty switch roles to keep from becoming typecast. The role of Rose Nyland kept her busy through 1993. Golden Girls ended production in 1992; the next season, Estelle Getty, Rue McClanahan, and Betty White reprised their roles for one season on Golden Palace.
Rue McClanahan, Vicki Lawrence, and Betty White in Mama's Family.
During the 1990s, Betty continued her television work. She had a regular role on Maybe This Time where she played Shirley Wallace, a much-married woman, who pushes her daughter, recently divorced, into a relationship, when she just wants to run the family coffee shop and avoid dating altogether. She also was in all 30 episodes of Ladies Man, where she again plays the mother of the main character. He is trying to raise a daughter from his first marriage and a daughter from his current marriage while dealing with a wife, and ex-wife, and a mother.
As the new century turned over in 2000, at 78, Betty just continued to add to her acting credits. She had regular roles on Boston Legal and The Bold and the Beautiful. She also starred in Hot in Cleveland for its entire five-year run. She continued appearing on a variety of television shows during that decade.
During her career, she was nominated for 21 primetime Emmys and won five. She also won 2 daytime Emmys. She is the only woman to be nominated in every comedy category. She was inducted into the Hall of Fame in 1995 and received a star on the Hollywood Walk of Fame.
Betty loves animals and is an advocate for many animal associations including the Los Angeles Zoo, the Morris Animal Foundation, and the African Wildlife Foundation. She received the Humane Award in 1987 and had a plaque installed near the gorilla exhibit at the Los Angeles Zoo to commemorate her work there.
It's hard to know what she will attempt next. She was the oldest person to host Saturday Night Live which she did in 2010. She appeared on the original Tonight Show with Jack Paar and has appeared with Jay Leno and Jimmy Fallon. She has been on the Howard Stern Show, the Simpsons, and one of my favorites, Madame's Place. She has guest starred in both comedies and dramas. She produced Betty White's Off Their Rockers, where senior citizens played pranks on younger people.
Considering her real name is Betty, not Elizabeth, it's ironic that her first television role was in Life with Elizabeth and her first movie was portraying Elizabeth Ames Adams.
At 95, how has she kept so young? If you ask her co-stars from Hot in Cleveland, they will tell you that she survives on hot dogs, French fries, Diet Coke, and red licorice. Who am I to argue?
One of her best awards came in 2010 when she was made an Honorary Forest Ranger. Considering that in 1940 that field was closed to her, when she received her honorary title, one-third of forest rangers were women.
When asked about why she loves performing, Betty said, "To be able to talk to that camera—the camera became your best friend. You're looking into that little camera lens and they're looking into your soul, because they're right into your eyes. You can't be phony. You can't fake it."
No one has ever accused Betty White of being a fake or a phony. Everyone she comes in contact with seems to love her. The camera was her best friend, but we all became her friends through those camera portrayals.
What a wonderful personality. What a wonderful career. What a wonderful legacy.
$10000 Pyramid, Advise and Consent, African Wildlife Foundation, Allen Ludden, Betty White, Betty White's Off Their Rockers, Boston Legal, Date With the Angels, Dick Barker, Elizabeth Ames Adams, Entertainment Tonight, Georgia Engel, Golden Palace, Hot in Cleveland, Jack Paar Tonight, Ladies Man, Lane Allan, Life With Elizabeth, Los Angeles Zoo, Macy's Thanksgiving Parade, Madame's Place, Mama's Family, Match Game, Maybe This Time, Morris Animal Foundation, Saturday Night Live, The Betty White Show, The Bold and The Beautiful, The Golden Girls, The Howard Stern Show, The Mary Tyler Moore Show, The Simpsons, To Tell The Truth, Tournament of Roses Parade
"Time to Get Things Started" →
4 thoughts on "The White Stuff"
Stars in Hot in Grafton
That is an interesting jump to make from park ranger to TV star! I had no idea all the things she did. I only know her as an older lady who gets honored a lot. By the way, what is Madame's Place? Not a show title I recognize.
Yes, she's pretty amazing. Staying involved and busy is probably how she's stayed young. I would tell you more about Madame's Place, but after next Monday you will know it all. How's that for a big hint.
Nicole Salm
Learned a lot I did not know about a wonderful woman, wonderfully written and entertaining!
She's on my list of people you want to have at your dinner party.
Check out my new four-volume series titled Classic Television: The Stories Behind Your Favorite Television Shows and Stars, Volumes 1-4 on Amazon. Volume 5 will be released in 2021.


Yesterday's Question answered below: What does it mean when they say you're point is moot?
Birthdays: Caligula 12AD*, Commodus 161AD**, Amilcare Ponchielli, Eldridge Cleaver, Buddy Hackett, James Coburn, Itshak Perleman, Van Morrison, Arthur Godfrey, Richard Baseheart, Rocky Marciano. Alan J. Lerner, Dan Rather, Maria Montressori (of the Montressori Method of education), Daniel Saroyan, Richard Gere, Chris Tucker is 39.
Yesterday's Question: What does it mean when they say you're point is moot?
Answer: From an old English law term meaning your point is irrelevant or pointless due to a change in circumstance.
Question: What does it mean when they say you're point is moot?
Yesterday's Quiz answered below: Where in America is Spuyten Duyvil (Spinning Devil) Creek?
Lenin survived, Fanny was executed and the Communist police terror consumed all remaining critics of the Bolshevik Revolution. Founder of the Communist Secret police Felix Derzhinsky said: Our purpose is not to find justice, but to mete out retribution!" In twenty months they jailed and executed more Russians than the Tsar's police did in the entire Nineteenth Century.
It was never really a red telephone, more a coded teletype machine. It was to prevent misunderstandings like the Cuban Missile Crisis.
Yesterday's Question: Where in America is Spuyten Duyvil (Spinning Devil) Creek?
Answer: It is the smallest body of water dividing Manhattan island from the Bronx at the very top of the island. It's believed that at the time of the Revolution that area had a small whirlpool and was dangerous for small boats.
Quiz: Where in America is Spuyten Duyvil (Spinning Devil) Creek?
Question: After burning Washington in 1814, the British task force turned to attack Baltimore (Rockets Red Glare, etc.). Why Baltimore?
Birthdays: King James II Stuart, John Locke, Oliver Wendel Holmes Sr., Jean Dominique Ingres, Charlie Parker, Preston Sturges, Ingrid Bergman, William Friedkin is 73, Dinah Washington, George Montgomery, Slobodan Milosevic, Robin Leach, Richard Attenborough is 88, Donald O'Connor, Elliot Gould, Rebecca DeMornay, Joel Schumacher, choreographer Mark Morris, Charles Kettering inventor of the automobile ignition, Michael Jackson would have been 53. 29 AD- Estimated date of the beheading of John the Baptist.
1893- Whitcomb Judson invented the zipper. 1896- Chop Suey invented in New York City.
1914- Mass march of women in black with muffled drums down New York's Fifth Avenue to demand the U.S. stay out of World War One. 1916- FeldMarshals Paul von Hindenberg und Eric Ludendorf were given overall command of the Germany's armies, and in effect run their country as well. This was the opposite of the great Clauswitz's rules that war should be subservient to diplomacy and never waged for it's own sake.
The Kaiser, so belligerent at the beginning of the war was by this point was merely a figurehead. To contribute to the war effort he agreed to limit his meals to four courses and drink beer instead of champagne. War is Hell ! He had a dummy trench built by a movie company on his palace grounds so he could be photographed congratulating frontline soldiers without ever having to actually go there himself.
Answer: The US Navy couldn't hope to challenge the British fleet, so they issued letters of mark, i.e. legal piracy licenses to private ships. These pirates raised hell with British commerce. Baltimore was seen as a important home base for these privateers.
Yesterday's Answer Below: Hurricane Irene is hitting the North Carolina coastal town of Nag's Head. How did Nag's Head get it's name?
Birthdays: Johann Wolfgang von Goethe, Leo Tolstoy, George Villiers the Duke of Buckingham- minister of James I, O'Flagherty, Donald O'Connor, Charles Boyer, Karl Boehm, Bruno Bettleheim, Ben Gazzara, Jack "King" Kirby, Janet Evans, Ron 'Louisiana Lightning' Guidry, Jason Preistley, Daniel Stern, Shania Twain, Charles Solomon, Jack Black is 42.
79 a.d.- POMPEII AND HERCULANEUM DESTROYED-The great volcano Versuvius erupted, burying the two Roman cities. The Emperor Titus rushed a fleet commanded by the natural scientist Pliny to rescue as many as he could. Pliny was overcome by the sulphurous fumes and died. His son, Pliny the Younger, eyewitnesses it all and wrote a moving account of the tragedy in his 'letters'. Scientists have been digging at the site of Pompeii since it's rediscovery in 1726, but estimates are there's as many as 30,000 skeletons still buried.
390AD-This was the Feast of Saint Augustine of Hippo. He was the Saint who tried every weird orgiastic cult he could find before converting to Christianity, He drove his mother Saint Monica crazy but his experiences helped him develop an answer to every anti-Christian argument. His famous book was "the City of God". For a Saint he could have done stand-up. He was famous for one liners like when someone asked him "What did God do before he created the world?" Augustine answered: "He made a hell for people who ask stupid questions !" His other great motto was "Lord, Make me Chaste- but not just yet..."
1678- THE POPISH PLOT- A man named Titus Oates came before King Charles II and the Parliament and declared he had uncovered a plot by English Catholics, Jesuits , the Bishop of Armaugh and the Roman Pope to kill Charles, enthrone his Catholic brother James, burn London and land an army of mercenaries to force the English people back into Roman Church by force! Odds Fish! King Charles at first laughed it off but the Privy council and public took him seriously.
There may have been one or two forlorn Catholic schemes but nothing on the scale Oates proclaimed, yet England went crazy for the next several months arresting and executing anybody accused. Titus Oates became very rich and famous but he finally was caught in his lies and sent to prison. When a mob of anti-Catholic Londoners attacked the carriage of the kings mistress Nell Gywnn thinking it was one of Charles' French tootsies Nell poked her head out of the carriage and cried:"Peace be with you Good Citizens! I am the PROTESTANT Whore!" the crowd cheered.
1776 – The day after George Washington's Army was defeated by the British in Brooklyn this day heavy rain and fog cancelled any actions. After the battle the British pushed the colonials up against the East River and could have brought up their fleet from Staten Island, captured Washington's army and destroyed the Revolution while the ink was still wet on the Declaration of Independence.
1945- Chinese Communist Mao Tse Tung or MaoZseDong, conferred with Generalissimo Chiang Kai Chek over how to keep the Civil War from starting up again now that the War with Japan was over. The meeting was arranged by American Ambassador Patrick Hurley, an Oklahoma senator who greeted Mao and the Chiang with a loud Indian-style war whoop. We don't know what Mao and Chiang thought of this curious form of welcome, but they couldn't stand one another. Almost as soon as their conference was over the Chinese Civil War began again. Mao drove Chiang to exile in Taiwan in 1949.
1963- Dr. Martin Luther King gave his "I Have a Dream" speech in front of the Lincoln Memorial at the climax of the first ' Poor People's March 'on Washington". Organizer A. Phillip Randolph conceived a poor people's march taking weeks not unlike the Bonus Marchers of 1929. The sympathetic John F. Kennedy administration prevailed upon them to keep it to one day to reduce the chance of violence and maximize media exposure. They had planned for 100,000 but they got 400,000. Movie stars like Sidney Poitier, Marlon Brando, even Charlton Heston attended.
Yesterday's Quiz: Hurricane Irene is hitting the North Carolina coastal town of Nag's Head. How did Nag's Head get it's name?
Answer: It got it's name thanks to the infamous Blackbeard the Pirate. He hung a lantern around the neck of an old horse and had it walk up and down the beach during bad weather. Ships out at sea would see the light and think it was a ship riding safely at anchor. They would steer towards the light and get smashed up on the dangerous schoals, proving easy plunder for the pirates.
Quiz: Hurricane Irene is hitting the North Carolina coastal town of Nag's Head. How did Nag's Head get it's name?
Question: One of these men was not alive at the same time as the others. Which one?
1917- Straight Shooting, the first film directed by John Ford released. Before that Ford did bit parts and stuntwork.
1950- NBC and General Foods abruptly cancelled the hit television show "the Aldrich Family" when a pamphlet called Red Channels accused one of the show's stars Jean Muir, of being a communist.
Yesterday's Question: One of these men was not alive at the same time as the others. Which one? Napoleon, Hokusai, Washington, Moliere?
Answer: Moliere was alive a century earlier.


text:
Long-term observational study in Japanese hemodialysis patients who completed a 3-year clinical study of lanthanum carbonate
Takashi Shigematsu1Email author,
Shigeo Negi1 and
Masaki Ohya1
Lanthanum carbonate (LC), an effective phosphate (P) binder, is widely used to manage hyperphosphatemia in hemodialysis patients. However, the long-term safety of LC treatment in clinical practice has not been completely established.
In an observational multicenter study, we retrospectively investigated the long-term tolerability in Japanese hemodialysis patients who had completed a 3-year phase III extension study of LC. Among 39 patients who completed the phase III extension study, those who gave written informed consent to allow a retrospective examination of their medical records for up to 8 years were enrolled. During the period spanning 2009 to 2013, a tolerability assessment was performed by monitoring adverse events, laboratory parameters, and vital signs.
Among the 34 enrolled patients, 30 were included for analysis. In this 5-year follow-up observational study, 18 of 30 patients (60.0 %) received LC with or without some other P binders (PBs), 10 patients (33.3 %) switched from LC to another PB, and 2 patients (6.7 %) did not use PB. During the phase III study, 16 patients (53.3 %) experienced a drug-related adverse event, with the most common being gastrointestinal disorder, already known to be a common adverse event of LC. No drug-related adverse events were reported during the follow-up observational study. Five of 18 patients (27.8 %) who continued LC and 3 of 12 patients (25.0 %) who did not continue LC experienced serious adverse events during the follow-up observational study. However, none of these events except for constipation were drug-related.
Mean serum P concentrations was kept within the guideline-recommended management target range during the study period. No clinically significant changes in laboratory parameters and vital signs were observed except for pronounced decreases in intact parathyrois hormone (PTH) and blood pressure during the follow-up observational study period.
In patients who completed a 3-year phase III extension study of LC, there was no evidence of delayed adverse events or any increase in the incidence of LC-related adverse events with increasing LC exposure for up to 8 years.
UMIN-CTR UMIN000015227
Lanthanum carbonate
Phosphate binders
Hyperphosphatemia
In chronic kidney disease (CKD) patients, urinary excretion of phosphate (P) is compromised due to renal failure, and hyperphosphatemia is therefore likely to occur. When hyperphosphatemia persists for a prolonged period, the risk of cardiovascular disease due to vascular calcification increases, resulting in extremely poor patient prognosis [1–5]. Consequently, the long-term management of the serum P concentration in dialysis patients is considered to be an important risk management item for improving patient prognosis. The "Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder" published by the Japanese Society for Dialysis Therapy (JSDT) recommends that serum P concentrations be managed within the range of 3.5 to 6.0 mg/dL [6].
Lanthanum carbonate (LC), an effective non-calcium (Ca) P binder (PB), is widely used to manage hyperphosphatemia in patients with CKD on dialysis. Studies evaluating the efficacy and safety of LC administration over 2, 3, and 6 years have consistently reported that LC is well tolerated with no evidence of safety-related issues [7–10]. Despite this evidence supporting its safety, concerns over the long-term safety of LC persist because some reports have suggested the potential risks of lanthanum (La) deposition and toxicity in the gastrointestinal tract, bone, liver, and central nervous system [11–15]. These safety concerns would appear to be at least partially based on the known toxicities of aluminium (Al)-containing P binders (PBs), which were commonly used between 1970 and 1990. Accumulation of Al due to long-term use of these binders in patients with CKD caused serious complications including encephalopathy, osteomalacia, proximal myopathy and microcytic anaemia [16]. Consequently, Al-containing PBs were contraindicated in 1992 for use in dialysis patients. A recently reported systematic review and meta-analysis of randomized controlled trials concluded that LC is well tolerated and more effective than placebo on a short-term basis in the treatment of hyperphosphatemia in dialysis patients, but its long-term tolerability and safety still needs further investigation [17].
Therefore, in this observational multicenter study, we retrospectively investigated long-term (for up to 8 years) tolerability in Japanese hemodialysis patients who had completed a 3-year clinical study of LC [10].
Study design and patients
This was a retrospective, observational multicenter study conducted at 10 Japanese dialysis facilities in patients with end stage renal disease (ESRD) undergoing hemodialysis and who had completed the 3-year phase III extension study of LC. The phase III study consisted of the original 1-year open-label study [18] and an additional 2-year open-label study [10]. One hundred and forty-five patients were enrolled in the phase III study, and after 1 year of treatment, 63 patients continued with further LC treatment for up to 3 years [10]. Among the 39 hemodialysis patients who completed the phase III study, patients who gave written informed consent to allow the retrospective examination of their medical records for up to 8 years (including the 3-year period of the phase III study) were enrolled in this follow-up observational study. Five patients who were assigned to placebo during the 6-week double-blind phase were excluded from being potential study candidates. The original 1-year study was performed during 2005 and 2006, and an additional 2-year study was performed from 2006 to 2008. The study period of this follow-up observational study was from 2009 to 2013. The study was registered in UMIN-CTR: UMIN000015227.
Using medical records, patient history including underlying diseases was examined at baseline of the phase III study. The primary endpoint was incidence of adverse events over a period of up to 8 years. Additionally, we investigated changes in the dosage of LC and PB other than LC and cinacalcet and the changes in biochemical and hematologic parameters and vital signs.
All variables were analysed by calculating descriptive statistics: frequency tables for categorical variables and the mean, standard deviation (SD) for continuous variables. The mean changes from baseline and their two-sided 95 % confidence intervals were calculated for laboratory parameters and vital signs. Comparisons between continuous variables were performed using the Wilcoxon signed-rank test and paired t test. In addition, we performed an ANOVA test. A value of p < 0.05 was considered to be statistically significant.
The study was conducted in accordance with principles that have their origin in the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies published by Ministry of Health, Labour and Welfare. The central institutional review board at Wakayama Medical University approved the study protocol, and written informed consent was obtained from each patient before the enrollment. The investigators retrospectively examined the patients' medical records in a manner that fully protected the patients' privacy.
Study patients
Among the 34 patients who enrolled in this follow-up observational study, 30 patients were included for analysis, and 4 patients whose data were not available were excluded from analysis. The excluded patients consisted of 2 patients lost to follow-up, 1 patient who had a renal transplantation, and 1 patient who withdrew consent.
Table 1 shows the baseline demographic characteristics of the 30 study patients. The average age was 54.7 years, and the male/female ratio was 21/9. The mean time on dialysis was 98.0 months, and the most common underlying disease was chronic glomerulonephritis, which was present in 50.0 % of patients. A significant proportion of patients had complications commonly associated with dialysis such as renal anaemia, hypertension, and secondary hyperparathyroidism (86.7, 76.7, and 70.0 %, respectively). The mean serum P, corrected Ca, and intact parathyrois hormone (PTH) concentrations were 7.8, 9.3, and 283.1 pg/mL, respectively.
Baseline demographic characteristics of the study patients
Total (n = 30)
Male (n)
21 (61.8 %)
Female (n)
9 (26.5 %)
62.4 ± 7.4 (Male)
50.6 ± 8.3 (Female)
Time on dialysis (months)
Underlying diseases causing renal failure
Chronic glomerulonephritis (n)
Diabetic nephropathy (n)
Chronic pyelonephritis (n)
2 (6.7 %)
IgA nephropathy (n)
Polycystic kidney (n)
Focal sclerosing glomerulonephritis (n)
Renal anemia (n)
Hypertension (n)
Secondary hyperparathyroidism (n)
Serum P (mg/dL)
Serum corrected Ca (mg/dL)
Serum intact PTH (pg/mL)
Data are given as mean ± standard deviation or number
P phosphate, Ca calcium
Changes in the dosage of phosphate binders and cinacalcet
Following manufacturing and marketing approval in October 2008, LC was launched onto the market in March 2009. This meant that LC had not been released for general clinical use during the final stages of the phase III study. Thus, LC could not be used for a certain period until it was adopted by dialysis facilities following its release onto the market.
The mean dose of LC at the start of the phase III study was 1700.0 ± 879.4 mg/day. This dosage was generally maintained during the phase III study, but was reduced following the phase III study because 18 of 30 patients (60.0 %) received LC with or without some other PBs such as Ca carbonate or sevelamer hydrochloride. In 10 of 30 patients (33.3 %), the PB was switched from LC to another PB, and in 2 of 30 patients (6.7 %) PB was no longer used. After cinacalcet was launched in January 2008, there was a steady yearly increase in the number of patients receiving this drug during the follow-up observational study. The mean dose of cinacalcet at the start of the follow-up observational study was 40.0 ± 12.9 mg/day, and this dose was generally maintained for the duration of the study (Table 2).
Dosage changes in phosphate binders and cinacalcet
Phase III study (1-year study and additional 2-year study)
5-year follow-up observational study
Dosage (mg/day)
Start (2005)
1 year after (2006)
2 years after (2007)
1700.0 ± 879.4 (750–3000) (n = 30)
1500 (n = 1)
863.6 ± 452.3 (250–1500) (n = 11)
2133.3 ± 766.9 (1000–3000) (n = 15)
Sevelamer hydrochloride
1968.8 ± 1263.8 (750–4500) (n = 8)
2035.7 ± 940.2 (750–3750) (n = 7)
1875.0 ± 1131.9 (750–3750) (n = 10)
40.0 ± 12.9 (25–50) (n = 10)
41.4 ± 21.8 (25–100) (n = 16)
Data are given as mean ± standard deviation, range and number
Incidence of adverse events
Drug (LC)-related adverse events that occurred during the phase III study are listed in Table 3. Sixteen patients (53.3 %) experienced a drug-related adverse event during the phase III study. None of the 30 patients experienced any drug-related (any PB including LC) adverse events during the 5-year follow-up observational study.
Drug-related adverse events during the phase III study
Drug-related adverse events (SOC/PT)
Patients with events, 16/30 (53.3 %)
Number of patients
Abdominal discomfort
Abdominal pain, upper
Abdominal pain, lower
Faeces, soft
General disorders and administration site conditions
Flank pain
C-reactive protein increased
SOC System Organ Class, PT Preferred Term (MedDRA ver. 18.0)
A total of 16 patients experienced 103 cases of drug-related adverse events, but all of these events except for 1 event were not serious. The 1 serious adverse event was constipation reported as "worsening of constipation" by the investigator and which resolved without treatment. The most common drug-related adverse events were nausea and vomiting, which occurred in 12 patients (40.0 %).
Serious adverse events that occurred during the phase III study and 5-year follow-up observational study are listed in Table 4. None of these serious adverse events except 1 event (constipation mentioned above) were drug-related. There were 3 deaths. The causes of death were cardiac failure (2 cases) and 1 case of pneumonia. Two patients (6.7 %) experienced a serious adverse event during the phase III study. During the 5-year follow-up observational study, 5 of 18 patients (27.8 %) who continued LC use and 3 of 12 patients (25.0 %) who did not continue LC (10 patients switched to another PB and 2 patients did not use PB) experienced serious adverse events.
Serious adverse events during the phase III study and 5-year follow-up observational study
Patients who continue LC
Patients who did not continue LC
Patients with events 2/30 (6.7 %)
Patients with events 5/18 (27.8 %)
Pyelonephritis acute
Neoplasms benign, malignant, and unspecified (including cysts and polyps)
Nervous system disorder
Cerebral haemorrhage
Myocardial ischaemia
Cardiac valve disease
Cardiac failure
Cardiac failure acute
Peripheral arterial occlusive disease
Upper gastrointestinal haemorrhage
Surgical and medical procedures
Foot amputation
aOutcome was death
Mean serum P concentrations
Figure 1 shows the changes from baseline (at the start of phase III study) in mean serum P concentrations during the 8-year study period. Mean serum P concentrations decreased from 7.8 mg/dL at baseline to 5.2 mg/dL after 3 years and 5.3 mg/dL after 8 years, thus remaining within the management target range (3.5–6.0 mg/dL) recommended in the JSDT guidelines [6] during the entire study period (Fig. 1a). The mean serum P concentration in patients who continued LC use did not differ significantly from that observed in the patients who did not continue LC (Fig. 1b).
Mean serum P concentrations at the start of phase III study and at various time points over the 8-year period covered by the study. a All patients, b Patients who continued LC or did not continue LC. Data are given as mean ± standard deviation (n = number of patients in a specific year)
Laboratory parameters and vital signs
Laboratory parameters and vital signs of all patients are shown in Table 5. Several parameters and vital signs showed statistically significant changes after 4 or 8 years. Of those parameters, the decrease in intact PTH and blood pressure would appear to be clinically significant. The mean changes from baseline after 8 years were −103.45 pg/mL, −18.83 mmHg (systolic blood pressure (SBP)), and −13.39 mmHg (diastolic blood pressure (DBP)), respectively. Table 6 shows the laboratory parameters and vital signs of patients who continued to receive LC. In those patients, the summary statistics did not differ from those observed in all patients.
Laboratory parameters and vital signs of all patients
4 years after
4 years mean change ± SEM (95 % CI)
P (mg/dL)
5.8 ± 1.0***
−2.19 ± 0.29 (−2.80, −1.59)***
−.51 ± 0.35 (−3.24, −1.79)***
Corrected Ca (mg/dL)
−0.11 ± 0.13 (−0.38, 0.16)
0.11 ± 0.11 (−0.12, 0.34)
Intact PTH (pg/mL)
180.7 ± 126.6***
179.1 ± 131.7*
−103.95 ± 27.20 (−160.55, −47.35)***
−103.45 ± 43.91 (−194.76, −12.14)*
Na (mEq/L)
139.2 ± 3.0
138.3 ± 3.3*
−1.20 ± 0.66 (−2.56, 0.16)*
K (mEq/L)
0.39 ± 0.10 (0.19, 0.60)
Cl (mEq/L)
Glucose (mg/dL)
17.00 ± 23.91 (−37.08, 71.08)
2.90 ± 8.10 (−15.43, 21.23)
CRP (mg/dL)
RBC (×104/μL)
327 ± 39
WBC (/μL)
5803 ± 1474
Hb (g/dL)
Ht (%)
Plt (×104/μL)
Serum Alb (g/dL)
3.9 ± 0.3*
−0.13 ± 0.05 (−0.23, −0.02)*
ALP (U/L)
2.19 ± 18.32 (−35.54, 39.92)
LDH (IU/L)
5.65 ± 6.52 (−7.86, 19.16)
23.91 ± 7.45 (8.46, 39.37)
AST (U/L)
ALT (U/L)
γ GTP (U/L)
9.38 ± 3.66 (1.81, 16.94)
Total bilirubin (mg/dL)
Creatinine (mg/dL)
11.2 ± 2.0***
Uric acid (mg/dL)
7.7 ± 1.4**
−0.84 ± 0.32 (−1.50, −0.17)**
BUN (mg/dL)
62.6 ± 16.6**
−9.81 ± 2.90 (−15.78, −3.84)**
BUN after dialysis (mg/dL)
20.0 ± 5.7**
−7.39 ± 1.32 (−10.1, −4.66)***
TG (mg/dL)
−5.11 ± 10.69 (−27.57, 17.36)
Total cholesterol (mg/dL)
−7.56 ± 5.43 (− 19.13, 4.00)
−2.00 ± 8.45 (−20.01, 16.01)
HDL-C (mg/dL)
6.42 ± 2.29 (1.62, 11.2)
SBP (mmHg)
144.2 ± 21.4***
−19.13 ± 5.19 (−29.89, −8.37)***
DBP (mmHg)
77.4 ± 13.2***
−10.26 ± 3.69 (−17.92, −2.6)**
HR (beats/min)
Data are given as mean ± standard deviation (n)
CI confidence interval
V.S. At the start, ***P < 0.001, **P < 0.01, *P < 0.05
Laboratory parameters and vital signs of patients who continued LC use
1 year after
218.9 ± 141.2**
165.4 ± 25.9*
12.3 ± 1.6*
69.4 ± 12.1*
153.3 ± 17.4**
LC lanthanum carbonate
LC is widely used to manage hyperphosphatemia in patients with CKD on dialysis and has contributed to improved clinical outcomes in these patients. The short-term safety profile of LC has been reported [19]; the most common adverse events of LC- and Ca-containing PB were gastrointestinal reactions. No significant difference was found in nausea (RR 1.72, 95 % CI 1.00–2.98, p = 0.05), vomiting (RR 2.17, 95 % CI 0.87–5.41, p = 0.10), diarrhoea (RR 1.26, 95 % CI 0.84–1.89, p = 0.27), or constipation (RR 0.78, 95 % CI 0.50–1.21, p = 0.27) between the two treatments.
Some studies were evaluated the efficacy, tolerability, and safety of LC monotherapy over 2 years [7], 3 years [8], and 6 years [9] have consistently reported that LC is well tolerated, with no evidence of safety concerns. The majority of LC adverse drug reactions were related to the gastro-intestinal tract (mainly nausea, diarrhoea, and flatulence) [9] and are primarily mild/moderate in severity, consistent with those observed with other phosphate binders. However, there is no insufficient safety data for a prolonged period or for Japanese.
Accordingly, the authors think that it is important to accumulate more evidence of the long-term effects of LC treatment in the clinical practice and explore how LC can be used for a prolonged period in a safe and appropriate manner.
Therefore, we retrospectively investigated the long-term tolerability of LC among Japanese hemodialysis patients who completed the phase III study study of LC treatment, in an observational multicenter study in order to follow safety outcomes for further 5 years regardless of these patients' LC administration. In this follow-up observational study, 18 of 30 patients (60.0 %) received LC with or without some other PBs, and in 10 of 30 patients (33.3 %), the PB was switched from LC to another PB and in 2 of 30 patients (6.7 %) PB was no longer used.
During the phase III study, LC-related adverse events occurred in 16 patients (53.3 %); however, no adverse events that were considered by the investigators to be related to any PB, including LC, were reported during the 5-year follow-up observational study. Although the dosage of LC was reduced in some patients and other patients switched to another PB from LC after the phase III study, these results strongly suggest that no evidence exists of delayed adverse events after 3 years of LC exposure or any increase in the incidence of LC-related adverse events with increasing LC exposure.
The most common drug-related adverse events that occurred during the phase III study were vomiting and nausea, which are already known to be common adverse events associated with LC [20]; however, there were no treatment discontinuations due to gastrointestinal adverse events. Hutchison et al. reported that no gastrointestinal events occurred in US patients after 3 years of LC exposure or in European patients after 4 years of exposure [9]. These results indicate that long-term LC treatment is possible provided gastrointestinal events that tend to occur more frequently in the early phase of treatment can be controlled.
Another potential safety concern of LC treatment is toxicity in bone, liver, and the central nervous system [11–15]. The long-term safety profile of LC in hemodialysis patients receiving treatment for up to 6 years have been reported and appear to show no evidence of adverse effects on the liver, bone, or the central nervous system [9].
Two patients (6.7 %) during the phase III study, 5 of 18 patients (27.8 %) who continued LC use and 3 of 12 patients (25.0 %) who did not continue LC experienced a serious adverse event during the 5 year follow-up observational study; however, all of these events except for 1 were not drug-related. The types of serious adverse events are those peculiar to dialysis patients with multiple complications. There was no difference in frequency of serious adverse events between patients who continued LC and patients who did not continue LC.
La deposition in a mesenteric lymph node found at autopsy of an ESRD patient 3 years after LC administration was reported [21]. Although the clinical significance of this deposition of La is not clear, further investigation of its potential long-term toxic effects is needed. Thus, the long-term safety of LC treatment, especially in clinical practice, has not been completely established. In recent years, several case reports about La deposition in gastric mucosa have been published [22–25]. Although every report indicated for lanthanum deposition in gastric mucosa, there is no relationship to gastrointestinal symptoms. In a nod to these reports, further long-term and large number observation should be needed.
Although several laboratory parameters showed statistically significant changes after 4 or 8 years, none of these parameters except for intact PTH and blood pressure were clinically significant when the mean changes from baseline and their confidence intervals are taken into account. At the start of the follow-up observational study (2009), a pronounced decrease of more than 100 pg/mL in intact PTH was observed. This decrease may be due to the introduction of cinacalcet in 2008. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) also decreased significantly after 3 years. Although it is unknown why a clinically significant decrease in blood pressure was observed, the degree of decrease in SBP and DBP after 8 years (i.e. SBP −18.83 mmHg, DBP −13.39 mmHg) was a positive effect.
The serum P concentrations were maintained within the management target range (3.5–6.0 mg/dL) recommended in the JSDT guidelines [6] for the entire 8 years. The long-term therapeutic effects of LC and other PBs on hyperphosphatemia were also confirmed in this study.
Hyperphosphatemia has been shown to increase mortality among patients with CKD [26]. Given this finding, management of serum P in patients with CKD has been recognized as a treatment priority. Recent data suggest improved survival when PB is used in the dialysis of patients [27, 28]. The results of other studies also suggest that there is a survival benefit associated with LC treatment [29, 30].
The present study has several limitations, the first of which is selection bias. We selected the patients who had completed the phase III study of LC, so we cannot exclude the possibility that only patients with no safety issues were enrolled in the study. Another potential limitation, as with any other long-term follow-up study, is the small number of enrolled patients. Regardless of these limitations, the results of the present study revealed no evidence of delayed adverse events or any increase in the incidence of LC-related adverse events with increasing LC exposure.
This study was might not able to put out the conclusion to safety about LC, as there were a limited number of the cases available. However, these results are valuable to evaluate LC exposure for up to 8 years.
In patients who completed the 3-year phase III extension study of LC, no drug-related adverse events were reported during the follow-up observational study. Both patients who continued LC use and patients who switched to another PB experienced serious adverse events during the follow-up observational study; however, there was no difference in the frequency of these events in either group and no unexpected serious adverse events were observed. The observations reported so far are short-term, and none of them cover a period of more than 10 years. Thus, it appears that further detailed investigations are needed.
For a list of institutions and principal investigators (PIs) see the appendix. The authors wish to thank the staff at all investigational sites.
Mihama Hospital, Chiba, Japan (PI: Takehiko Sakai); Mihama Narita Clinic, Narita, Japan (PI: Kouichi Murakami); Mihama Sakura Clinic, Sakura, Japan (PI: Osamu Nagakawa); Shin Kashiwa Clinic, Kashiwa, Japan (PI: Yasuo Kimura); Meiyo Clinic, Toyohashi, Japan (PI: Yoshinari Tsuruta); Shigei Medical Research Hospital, Okayama, Japan (PI: Masaki Fukushima); Nakajima Tsuchiya Clinic, Hiroshima, Japan (PI: Misaki Moriishi); Shimazu Hospital, Kochi, Japan (PI: Isao Takeda); Kochi Takasu Hospital, Kochi, Japan (PI: Kenji Yuasa); Kitasaito hospital, Asahikawa, Japan (PI: Atsushi Wada).
This study was funded by Bayer Yakuhin, Ltd. TS received honoraria from Bayer Yakuhin, Ltd. for delivering lectures. SN and MO have no conflicts to disclose. Editorial support, including writing assistance with draft development was provided by SunFlare Co., Ltd.
TS (corresponding author) has planned this study, has searched literatures, and has analysed and evaluated study data. And TS also wrote this manuscript. SN has applied to the Ethical Review Board and extracted data. MO took a statistical step and supported to evaluate study data. All authors read and approved the final manuscript.
Department of Nephrology, Wakayama Medical University, 811-1 Kimiidera, Wakayama city Wakayama, 641-8509, Japan
Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–83.View ArticlePubMedGoogle Scholar
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.View ArticlePubMedGoogle Scholar
Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–8.View ArticlePubMedGoogle Scholar
Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006;70:351–7.View ArticlePubMedGoogle Scholar
Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519–30.View ArticlePubMedGoogle Scholar
Fukagawa M, Yokoyama K, Koiwa F, CKD-MBD Guideline Working Group; Japanese Society for Dialysis Therapy, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247–88.View ArticlePubMedGoogle Scholar
Finn WF, SPD 405–307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65:191–202.View ArticlePubMedGoogle Scholar
Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61–71.View ArticlePubMedGoogle Scholar
Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008;110:c15–23.View ArticlePubMedPubMed CentralGoogle Scholar
Shigematsu T, Group LCR. Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. Clin Exp Nephrol. 2010;14:589–97.View ArticlePubMedGoogle Scholar
Canavese C, Mereu C, Nordio M, Sabbioni E, Aime S. Blast from the past: the aluminum's ghost on the lanthanum salts. Curr Med Chem. 2005;12:1631–6.View ArticlePubMedGoogle Scholar
Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purif. 2005;23 Suppl 1:2–11.View ArticlePubMedGoogle Scholar
Drüeke TB. Lanthanum carbonate as a first-line phosphate binder: the "cons". Semin Dial. 2007;20:329–32.View ArticlePubMedGoogle Scholar
Aime S, Canavese C, Stratta P. Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate. Kidney Int. 2007;72:1162–3.View ArticlePubMedGoogle Scholar
Frazão JM, Adragão T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin Pract. 2012;120:c108–19.View ArticlePubMedGoogle Scholar
Parkinson IS, Ward MK, Kerr DN. Dialysis encephalopathy, bone disease and anaemia: the aluminum intoxication syndrome during regular haemodialysis. J Clin Pathol. 1981;34:1285–94.View ArticlePubMedPubMed CentralGoogle Scholar
Huang W, Liu J, Tang Y, Gao X, Di B, Zhang F. Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin. 2014;30:99–108.View ArticlePubMedGoogle Scholar
Shigematsu T, Lanthanum Carbonate Research Group. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Ther Apher Dial. 2010;14(1):12–9.View ArticlePubMedGoogle Scholar
Zhai CJ, Yang XW, Sun J, Wang R. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2014;47(3):527–35.View ArticlePubMedGoogle Scholar
Package insert of Fosrenol (Lanthanum Carbonate). Bayer Yakuhin, Ltd. 2013. version 8.Google Scholar
Davis RL, Abraham JL. Lanthanum deposition in a dialysis patient. Nephrol Dial Transplant. 2009;24(10):3247–50.View ArticlePubMedGoogle Scholar
Makino M, Kawaguchi K, Shimojo H, Nakamura H, Nagasawa M, Kodama R. Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. Pathol Int. 2015;65(1):33–7.View ArticlePubMedGoogle Scholar
Namie S, Hamabe S, Kawatomi M, Oda H, Nakazawa M, Nishino T. Investigation of deposition of lanthanum on gastric mucosa in hemodialysis patients with lanthanum therapy. Nihon Toseki Igakkai Zasshi. 2015;48(3):169–77.View ArticleGoogle Scholar
Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M. Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol. 2015;39(6):767–71.View ArticlePubMedGoogle Scholar
Rothenberg ME, Araya H, Longacre TA, Pasricha PJ. Lanthanum-induced gastrointestinal histiocytosis. ACG Case Rep J. 2015;2(3):187–9.PubMedPubMed CentralGoogle Scholar
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.View ArticlePubMedGoogle Scholar
Cannata-Andía JB, Fernandez-Martiwn JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84(5):998–1008.View ArticlePubMedGoogle Scholar
Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388–96.View ArticlePubMedPubMed CentralGoogle Scholar
Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin. 2009;25(12):3021–8.View ArticlePubMedGoogle Scholar
Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant. 2015;30(1):107–14.View ArticlePubMedGoogle Scholar


It is finally hot hot here in Botswana, and that means days of sitting around the house trying not to move. The water has been out for days, though luckily a friend has been sharing her Jojo tank water with me since I've exhausted my stores. The change in temperature has also brought bugs, and I'm seeing one of those giant spiders every other night. At least this means Crunchy has some moving targets to play with.
I've been busy since the last time I posted. I went to my old training village (Kanye) a couple weeks ago to help out with the training of the new group. Our Peace Corps doctor was nice enough to let me help out with session and I got to meet the new group of trainees. It was sort of surreal to see a group 6 months behind – my group members and I have been in this country for a while now. I think I'm finally over the hard part and I seem to be getting busier and busier every day.
This past week, I had a shadow named Adam. He's a trainee who spent the week with me living life like I do. We were surprisingly busy, spending time at the garden, school, and wellness workshop my counterpart was managing. Since Adam was my first visitor, I got to show him around and share what my daily life is like; it was pretty cool and I'm excited to get more visitors.
I'm still having issues with my organization, but have also found some other small project ideas that can occupy my time. I'm hoping to start a recycling program, plant trees around the village, and get some books for the local libraries while sifting through the problems at my primary assignment. I figure these will be activities with fewer barriers to success, so cross your fingers for my personal crusades.
Although I got a lot of support for my man-beard, it's just too damn hot now. I shaved it all off. I had actually forgotten what my face looked like underneath my mane since I began growing it in June. Upon removing the Jesus factor, it appears that I got about 10 years younger and lost a lot of weight. What will I do with my hands now when I'm lost in thought? Maybe the beard will return next winter.
To my fellow MSU football fans: 4 years in a row! Go green.
Awesome! Im soo happy to hear youre figuring things out with getting books to the libraries and recycling, sounds like a more feasible way to be greatly productive also i think i prefer non beard haha you look great though!!
I can't believe how much you're doing down there! You should definitely be happy with your success thus far. It's great to see some pictures of you, to actually see that you are doing well.
You sound like you are doing such wonderful things over there, I am so proud of you!
Everyone here is doing great!
Hi baby face, you also look a little sunburned. Sun Block at least 30 or more UPC (or what have you) will work good, do you need some?


text:
Jacob Gedleyihlekisa Zuma (Msholozi)
Date of Birth: 12 April 1942
Place of Birth: Nkandla, KwaZulu-Natal Province
Displaying 71-80 out of 582 results.
Vol 58 No 6 |
How to repeat the Mugabe mantra
Just as mounting political crises again threatened to overwhelm President Jacob Zuma he pulled out the land card to buy himself breathing space before the African National Congress's elective conference in nine months' time...
Zuma has long appeased traditional leaders as he sees their power as crucial to ensuring his own political survival and that of the ANC in 2019 (AC Vol 58 No 4 The state of Jacob Zuma's presidency)...
Zuma's anti-Gordhan play
President Jacob Zuma has become increasingly irritated with his respected Minister of Finance Pravin Gordhan who was widely praised after presenting a balanced budget on 22 February amidst trying economic circumstances (AC Vol 58 No 4 The state of Jacob Zuma's presidency)...
Zuma learned the limits of his power when he was forced to abandon plans to replace the then Finance Minister Nhlanhla Nene with David van Rooyen and ended up re-appointing Gordhan (AC 56 No 25 Jacob Zuma's costly week)...
The state of Jacob Zuma's presidency
With ten more months as leader of the African National Congress (ANC) President Jacob Zuma tried to shore up his government with a flurry of populist policies – long on rhetoric and short on detail – at the opening of Parliament on 9 February...
For the past year he has been locked in battle with President Jacob Zuma over sundry investigations into the well-connected Gupta family's influence on state spending decisions and presidential plans for multi-billion dollar nuclear power contracts to be awarded to Russian state companies (AC Vol 58 No 1 Power struggle goes nuclear)...
Global shocks, local differences
Infighting in the governing African National Congress is holding back economic policy reforms especially those in the state-owned enterprises regarded as one of President Jacob Zuma's remaining fiefdoms...
Power struggle goes nuclear
On South Africa's Reconciliation Day on 16 December President Jacob Zuma's speech in the North-West Province was brought to a halt when strong wind and heavy rain blew away the marquee where he was speaking...
Vol 57 No 25 |
The numbers game next year
After surviving an attempt by his opponents on the ANC National Executive Committee (NEC) to organise a no-confidence vote last month President Jacob Zuma is said to be reviving plans to purge his enemies in the cabinet (AC Vol 57 No 24 Clinging to the wreckage)...
MK vs JZ
General Siphiwe Nyanda was during the liberation struggle one of Jacob Zuma's closest confidants in the armed wing of the African National Congress (ANC) Umkhonto we Sizwe (MK) but has turned against him...
'Afrexit' on hold
South Africa may yet return to the court as its own human rights lawyers lodge ever more cases or after President Jacob Zuma leaves power (AC Vol 57 No 23 Starting the post-Zuma race)...
Clinging to the wreckage
The African National Congress looked more deeply divided than ever as fault lines over the presidency of Jacob Zuma deepened early this week...
Gordhan in ratings war
President Jacob Zuma and his allies are hoping rating agencies will downgrade South Africa's credit status to 'junk' sources among his supporters have told Africa Confidential...
Zuma has been gunning for Gordhan ever since he was obliged by the economic and business community as well as ANC leaders to reinstate him after his disastrous sacking of Finance Minister Nhlanhla Nene last December (AC Vol 56 No 25 Jacob Zuma's costly week)...
The politics of power
Too much truth
Foreign policy flip-flops
Key events in South Africa in 2019
Congress gets scratchy
Looking for a specific issue? Search our online archive of over two decades of Africa Confidential
Volume: 60 59 58 57 56 55 54 53 52 51 50 49 48 47 46 45 44 43 42 41 40 39 38 37
Number: 14 13 12 11 10 9 8 7 6 5 4 3 2 1


Click on one of the choices shown in the Explore Pathways box to highlight that portion of the pathway.
Macroautophagy, hereafter referred to as autophagy, is a catabolic process by which cells degrade long-lived proteins, organelles, and certain types of bacteria via lysosomes. Briefly, the autophagy pathway entails the development of a phagophore that envelopes cytoplasmic components and forms a double-membrane autophagosome that subsequently fuses with a lysosome for the digestion of its contents. Of importance to a wide range of researchers, the autophagy pathway is thought to be protective against several diseases, including neurodegeneration, myopathy, liver disease, and diabetes. Additionally, autophagy appears to have a complex role in cancer, as it has been reported to both promote and inhibit cancer.
Autophagy is initiated by the generation of phosphatidylinositol 3-phosphate [PI(3)P]-rich regions of the endoplasmic reticulum (ER) that form phagophores, which are also referred to as omegasomes due to their shape. PI(3)P is generated by hVps34, the catalytic subunit of the Beclin 1 complex, and is required for the recruitment of downstream autophagy components, such as WIPI1/2 and DFCP1. The ULK1/2 kinase complex, including ULK1, ULK2, ATG13, and RB1CC1, is also required for autophagy initiation. It positively regulates the Beclin 1 complex indirectly by promoting its release from microtubules and possibly directly by phosphorylating Beclin 1 and stimulating hVps34 activity.
Phagophore elongation is thought to require mATG9 and the Ubiquitin-like protein, LC3. mATG9 is a transmembrane protein found mainly in the Golgi network that transiently interacts with phagophores in an ULK1-dependent manner during nutrient starvation. These transient interactions may contribute to membrane delivery during phagophore elongation. LC3 is converted to LC3-II, which is commonly used as an autophagy marker, in two steps. LC3 is first cleaved by ATG4B to form LC3-I. LC3-I is then translocated to phagophores via the Ubiquitin-activating (E1)-like enzyme ATG7 and the Ubiquitin-conjugating (E2)-like enzyme ATG3 where it is conjugated to phosphatidylethanolamine (PE) to form LC3-II. LC3-II formation is positively regulated by PI(3)P effector proteins, such as WIPI1/2, and the ATG16L-ATG5-ATG12 Ubiquitin-like complex. Interestingly, RB1CC1 may interact with ATG16L, which suggests that the ULK1/2 kinase complex might also function during phagophore elongation. LC3-II also binds substrates for autophagic degradation, referred to as cargo, via different adaptor proteins. For example, during mitochondrial autophagy, or mitophagy, LC3-II binds to mitochondria via the BNIP3L adaptor protein.
Autophagosome formation occurs via the fusion of the phagophore double membranes into a sphere, but the mechanism by which this happens is not understood. GATE-16, which is closely related to LC3 and processed in a very similar manner to LC3, is only required for later stages of autophagosome maturation and might have a role in membrane fusion. Autolysosomal degradation is initiated when the autophagosome fuses with a lysosome, resulting in the disruption of the inner membrane and the digestion of its contents. LC3-II that is on the cytoplasmic side of the outer membrane avoids degradation and can be recycled via cleavage by ATG4B.
To learn more, please visit our Autophagy Research Area.


text:
Q: Save file in main UI I write a function, that save file to external storage:
public void saveBmp(Bitmap bmp) {
    File f = new File(Environment.getExternalStorageDirectory(), "test.jpg");
    FileOutputStream fos = null;
    try {
        fos = new FileOutputStream(f);
    } catch (FileNotFoundException e1) {
        e1.printStackTrace();
    }
    bmp.compress(CompressFormat.JPEG, 70, fos);
    try {
        fos.flush();
        fos.close();
    } catch (IOException e) {
        e.printStackTrace();
    }
    bmp.recycle();
}

Why android not warning me, that i'm using file system in main UI.
Is it right way or i need to use asynctask?

A: As per developer.android.com
*

The BitmapFactory.decode* methods, discussed in the Load Large Bitmaps
  Efficiently lesson, should not be executed on the main UI thread if
  the source data is read from disk or a network location (or really any
  source other than memory). The time this data takes to load is
  unpredictable and depends on a variety of factors (speed of reading
  from disk or network, size of image, power of CPU, etc.). If one of
  these tasks blocks the UI thread, the system flags your application as
  non-responsive and the user has the option of closing it (see
  Designing for Responsiveness for more information).

*
So what it suggests is you should not block the main UI thread by writing file to external storage. And it is strongle encouraged that you use AsyncTask

A: You can create something like that. But I advise you to create and write in the file in an AsyncTask because if there are too many data to write in the file it will cost you a lot of seconds and in those seconds the user will not be able to do anything with your app because the main thread ( the UI thread ) is used to do the writing. Now it depends on how you designed your app. Maybe you don't want to let the user do anything else while the file is created, but even then I would say that you could do the writing in an AsyncTask, and while the writing is done you could display a Loading gif, or something to inform the user that the saving is in progress.

redpajama_set_name: RedPajamaStackExchange